SCLC is an unforgiving, highly aggressive variant of lung cancer. It accounts for approximately 15% of the lung cancer cases globally and is also a major cause of cancer-related deaths.
The chemotherapy has been the mainstay in SCLC management. While response rate to chemotherapy is high, notably, almost all patients relapse after few months (PFS is typically 4.0 - 5.5 months) .
Immunotherapy, which changed treatment paradigm in Melanoma and NSCLC, has shown only modest benefit in SCLC patients. The latest positive result in the first line was reported from IMpower 133 trial in which addition of atezolizumab to chemotherapy resulted in 2 months of overall survival benefit over chemotherapy alone (12.3 months vs 10.3 months) in extensive-stage SCLC patients. These results were first such improvement reported in about 30 years. Based on these results, FDA approved atezolizumab + chemotherapy for first-line treatment.
We performed a detailed analysis of clinical trials to understand the following -
Please fill the form on the right side to receive our latest report via email.
We hope this report will serve as an important pre-read for the upcoming ESMO 2019 conference.
Oncofocus Research Team